<SEC-DOCUMENT>0001193125-14-069728.txt : 20140226
<SEC-HEADER>0001193125-14-069728.hdr.sgml : 20140226
<ACCEPTANCE-DATETIME>20140226161306
ACCESSION NUMBER:		0001193125-14-069728
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140226
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140226
DATE AS OF CHANGE:		20140226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		14644763

	BUSINESS ADDRESS:	
		STREET 1:		11494 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1318
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		11494 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d685397d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) February&nbsp;26, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1787 Sentry Parkway West</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Building 18, Suite 400</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Blue Bell,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19422</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (267)&nbsp;440-4200 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><U>Item&nbsp;8.01.</U></TD>
<TD ALIGN="left" VALIGN="top"><U>Other Events.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inovio Pharmaceuticals, Inc. (the &#147;Company&#148;) is filing this
Form 8-K current report to provide certain information as an update to the information provided in the Company&#146;s previous periodic filings with the Securities and Exchange Commission (the &#147;SEC&#148;) in order to reflect recent business
developments. A summary description of the Company&#146;s business is attached hereto as Exhibits 99.1 and is incorporated herein by reference. This Form 8-K, including the exhibits hereto, should be read in conjunction with the Company&#146;s Form
10-K annual report for the year ended December&nbsp;31, 2012, the Company&#146;s Form 10-Q quarterly reports for the quarters ended March&nbsp;31, 2013,&nbsp;June&nbsp;30, 2013 and September&nbsp;30, 2013 and the Company&#146;s Form 8-K current
reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;26, 2014, the Company issued a press release announcing its intention to offer and sell shares of its common
stock in an underwritten public offering, subject to market conditions and other factors, pursuant to the Company&#146;s effective Registration Statement on Form S-3 (File No.&nbsp;333-193698). The full text of the press release issued in connection
with the announcement is attached to this Form 8-K as Exhibit 99.2 and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01.</U></TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits.</U> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Updated Summary Business Description</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Inovio Pharmaceuticals, Inc. Press Release dated February 26, 2014</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;26, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d685397dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are engaged in the discovery and development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers
and infectious diseases. Our DNA-based SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza and also
generate strong T-cell responses to fight cancers and infectious diseases. Our preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), hepatitis&nbsp;C
virus, hepatitis&nbsp;B virus, HIV, and malaria vaccines. Our partners and collaborators include Roche, University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate
Technology in Health/Malaria Vaccine Initiative, National Institute of Allergy and Infectious Diseases, Merck, University of Southampton, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, HIV
Vaccines Trial Network and Department of Homeland Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our potential human products are in research and development phases. We have not
generated any revenues from the sale of any such products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue, collaborative research and development
agreements, grants and government contracts. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical
testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be
profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Historical
Importance of Vaccines </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe vaccines have saved more lives and prevented more human suffering than any other human invention. As recently as a
century ago, infectious diseases were the main cause of death worldwide, even in the most developed countries. Today, there is a vast range of vaccines available to protect against more than two dozen infectious diseases, especially for children.
Our society has found that the only way to control or even eliminate infectious diseases is consistent, widespread use of vaccines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Challenges Facing
Vaccines </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the advances made to quality of life as a result of the development and use of vaccines over the past century, several significant
challenges continue to exist. The technical limitations of conventional vaccine technology have constrained the development of new vaccines for other diseases. Development of vaccines based on conventional technology requires significant
infrastructure in research and manufacturing, and can be time consuming. Safety risks associated with conventional vaccine approaches may offset their potential benefits, as the conventional vaccines we have depended upon employ either weakened or
killed viruses or different parts of a virus as vaccines. Further, conventional vaccines are still grown in eggs or cells and harvested over periods of weeks with very inefficient manufacturing processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, it is important to note a changing dynamic in the broader vaccine marketplace. Traditionally, vaccines have been predominantly focused on the
pediatric market, intended to protect children from diseases that could cause them serious harm or death. Today, there is a growing interest in vaccines against diseases that may affect adolescents and adults, which include both sexually transmitted
diseases and infections that strike opportunistically, such as during pregnancy, in immuno-compromised individuals, and in the geriatric population. Furthermore, there is encouraging data from and ongoing development of immunotherapies against
cancers. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inovio&#146;s Solution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With our synthetic vaccine platform comprising our SynCon&reg; vaccine design process and proprietary electroporation delivery technology, we have developed a
preclinical and clinical stage pipeline of vaccines that we believe has the potential to be safer than traditional vaccines (our synthetic vaccines are non-live and non-replicating therefore they cannot cause the disease), have equivalent or
stronger immune-stimulating power than traditional vaccines (live viruses being the best at eliciting strong immune responses), are showing the potential to be used against diseases for which conventional vaccine technology cannot be applied, and
have added advantages with respect to development time and cost. Preclinical studies in animals and initial human clinical study data have demonstrated a favorable safety profile and best-in-class immune responses that suggest the potential efficacy
of our approach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Next Generation of Vaccines: Synthetic Vaccines </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Our synthetic vaccine
consists of a DNA plasmid encoding a selected antigen(s) that is introduced into cells of humans or animals with the purpose of having those cells produce the antigen encoded by the DNA instructions and consequently inducing an immune response to
the antigen. Production by these cells of the targeted antigenic protein(s) may trigger one or both of two immune responses: the production of antibodies, known as a humoral immune response, and/or the activation of T-cells, known as a cellular or
cell-mediated immune response. These responses may then neutralize or eliminate infectious agents (e.g. viruses, bacteria, and other microorganisms) or abnormal cells (e.g. malignant tumor cells). Synthetic vaccines have several advantages over
traditional vaccines in that they are non-pathogenic (meaning they cannot cause the disease), may be effective against diseases which cannot be controlled by traditional vaccines, and are relatively fast, easy and inexpensive to design and produce.
Synthetic vaccines are stable under normal environmental conditions for extended periods of time. Another potentially major advantage of synthetic vaccines is their relatively short development cycle. For example, synthetic vaccines against newly
identified viral agents may be developed within weeks or months, as opposed to the years often required to develop a traditional vaccine candidate. In the area of cancer, synthetic vaccines use a portion of the genetic code of a cancer antigen to
cause a host to produce proteins of the antigen that may induce an immune response. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Inovio&#146;s SynCon&reg; Vaccines </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our synthetic vaccines are designed to generate specific antibody and/or T-cell responses. Our SynCon&reg; technology provides processes that employ
bioinformatics, which combine extensive genetic data and sophisticated algorithms. Our design process is based on the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of
pathogens such as HIV, hepatitis C virus (&#147;HCV&#148;), human papillomavirus (&#147;HPV&#148;), influenza and other diseases. We synthetically create a new antigen that represents a consensus of the DNA make-up of these multiple strains of the
desired pathogen target. This synthetic consensus DNA sequence does not exist in nature (and is consequently patentable). This unmatched antigen has been shown to nevertheless induce a powerful immune response in humans against that antigen,
providing protection not only against multiple existing strains of the same sub-type that were used to develop this synthetic antigen but to also provide protection against newly emergent strains not used in designing the vaccine. Thus, the
SynCon&reg; technology allows us to develop universal vaccines against target pathogens. These SynCon&reg; synthetic vaccine constructs may provide a solution to the genetic &#147;shift&#148; and &#147;drift&#148; that is typical of infectious
diseases. SynCon&reg; immunogens are able to elicit broad, diverse immune responses, which in theory are important to protect against variable pathogens such as influenza, dengue, HCV and HIV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SynCon&reg; vaccine antigens are designed by aligning numerous primary sequences and choosing DNA-based triplets for the most common or important amino acid
at each site. These antigens are further optimized for codon usage, improved mRNA stability, and enhanced leader sequences for ribosome loading. The DNA inserts are therefore optimized at the genetic level to give them high expression capability in
human cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of the coded
antigen to enhance the overall ability of the synthetic vaccine to induce the desired immune response. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical studies have shown that immunization of mice and non-human primates using SynCon&reg; synthetic
vaccine constructs elicited an immune response against multiple, unmatched strains within specific sub-types of HIV, HCV, HPV, dengue, prostate cancer and influenza viruses. Vaccine candidates for all these diseases are being advanced through
preclinical and clinical studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Roche Collaboration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted an exclusive worldwide license to Roche to research, develop and commercialize our multi-antigen DNA immunotherapies targeting prostate cancer
and hepatitis B. Pursuant to the terms of our agreement, Roche holds an exclusive license for our DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of our CELLECTRA&reg; electroporation
technology for delivery of these vaccines. Roche also has an option to exclusively license up to five additional prostate cancer antigen targets in connection with a collaborative prostate cancer research program, and we have agreed to work
exclusively with Roche regarding such targets during the term of the research program, and beyond with respect to any of these targets if Roche exercises the option, and products resulting from such program. The exclusive rights granted to Roche do
not prevent us from working with products outside the collaboration with respect to our electroporation delivery technology and certain of our DNA expression technologies. We are collaborating with Roche to further develop INO-5150 and INO-1800.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our agreement, Roche will pay for preclinical and clinical development costs. Total milestone payments upon reaching certain
development and commercial milestones may potentially amount to $412.5 million. Additional development milestone payments could also be made to us if Roche pursues other indications with INO-5150 or INO-1800. In addition, we are entitled to receive
up to double-digit tiered royalties on product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d685397dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.2 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g685397g27m88.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>NEWS RELEASE </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Immediate
Release </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals Announces Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BLUE BELL, PA &#150; February&nbsp;26, 2014 &#150; Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) (&#147;Inovio&#148; or the &#147;Company&#148;), today
announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray&nbsp;&amp; Co. and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated are acting as joint bookrunning managers for the offering.
The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with and declared effective by the
Securities and Exchange Commission on February&nbsp;13, 2014. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. Copies of the preliminary prospectus supplement
and the accompanying prospectus relating to the securities being offered may also be obtained from Piper Jaffray&nbsp;&amp; Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or
email at prospectus@pjc.com; or from Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720 or email at syndicateops@stifel.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Inovio being offered, and shall not
constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
engaged in the discovery and development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Our DNA-based SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza and also generate strong T-cell responses to fight cancers and infectious diseases. Our preclinical development and
clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. Our partners and collaborators include Roche, University of
Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative, National Institute of Allergy and Infectious Diseases, Merck,
University of Southampton, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, HIV Vaccines Trial Network and Department of Homeland Security. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995 relating to our business,
including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results
achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated,
that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to
support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope
to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies,
whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary
to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital
market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, our Form 10-Q for the quarter ended September&nbsp;30, 2013, and other
regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to
market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Although the Company may elect to do so at some point in the future, the Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g685397g27m88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685397g27m88.jpg
M_]C_X0\[17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-#HP,CHR-B`P.3HP-CHQ,@```Z`!
M``,````!``$``*`"``0````!````Z:`#``0````!````4@`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```X%`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`.`"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`Z'ZP/^LPZXX8AR0V6?8A
M3/HD0)]6/T'\]O\`7^U?X+_@UV;9@;N>\<2J.5USI6'EMPLF\5Y#]FVO:XSZ
MCO3J]S6EON>%?24I)9V+]8.CYEEE>/DM<ZECK+9#F!K&':][GV-8S:Q5'_7+
MH37[6V66-_TC*GEGW[?=_824[B2KX6=AY]`R,.UMU1,;F]B.6/:?<Q_\AZL(
M*4DF61E_6OH.+<['.3Z]]<A].*Q^0YI&A9;]D9=Z3_\`C=B=&,I:1!/D@D#<
MT["2YQGU_P#JUZGI7VW8K^POHM9_WSV_VUNXN7BYE+<C$N9D4N^C96X/:?[3
M)2E"4?FB8^84)1.Q!3)*GU#JW3^F^F<VWT1<2*R6N<"6C<YOL:[\U&Q<K'S,
M>O*QGBVFT;F/$ZCYIJ4R22SJOK!TBW-^P59`?E%[J_3#7GW,GU!NV;/9L=^<
MDIS/KB[J[68WV(WC&EWKG&W;]WM]'?Z'Z;TOYSZ'^$_G%I_5\]0/2,<]2W?:
MH.[U/I[=SO1]:/\`"^EL]3_I^]'ZAU3!Z:QEF;:*66.V,)#C+H+]OL:[\UJ+
MC9%.5CUY-#M]-S0^M\$2UVK3#H<BI*DF)`$DP!R5CY'UNZ%2XL;>;W`P?08Z
MQO\`VZT>D[_/04[*2S,#ZQ='S[!31D`7.XJL!K>?ZC;0WU/^MK324__0WOK-
M_P"*K&_]!/\`S\]=NN(^LW_BJQO_`$$_\_/7;I*?->DX#^I]0&`'NKJM<]V0
MYO\`HZW[^#[?YWT_3W_G_I/S%V+_`*H]`=4:QCECB(%K7O\`4!_?]1SG;G?U
MU@?4H?Y:R/*BS\;F+N$E/#_5=]N!]8[<!SMPL]6FV-`YU!W4W;?WO2W_`.>N
MMZIU/%Z5@6Y^8XMHI`+MHW.))#&5L8/I/L>YK&+D\#_Q<O\`^/R/_/3D7_&=
M8\=+PJA]!^4'/_L5V%@_SO<GXH"<XQ/4K,DN&$I=@W,'K6+];*K:<06TLH(&
M5CW#9+7[O2=8['L=Z]-FQ_ZO7=7_`-V?T/Z.W3JZ!A,J;2\O?6P0RH.]*IH\
M*\?&]&EC?["PO\6F-6SH^1D@S9?D.:_R%8#&!=@EF`C.48WPQ.Q5C),(R/S$
M='!ZC]4.G9E+F,+F'LUY+V3\'DO9_6K>N!+^J_4_K;OL\CAUE!/LOK!_F[?S
M76?Z#)V^HS_MVI>MKSK_`!E7T.ZKA4,/Z:BE[KH[->YOHM/_`&U:Y2\J29^V
M=82!XH]/-CYD`0XQI.)'#+]CU_4J*?K!T`68IGUZVY.&XZ'?'J5;OW=_\U9_
M763]1NI2+NFOD?\`:B@'D`G;DU?];M]__77K1^I5=E?U5Z<VS1WI;@#^ZYSG
ML_Z#FK!Z[59T+ZQ,ZA0T^E8XY+`._P"9G4?VVO\`5_Z]_(4$@!*0&H!(9HFP
M"=+#U/7NI?LWI=V2TCUB/3H![V/]M?\`F?SC_P"0Q8?U'Z;`MZE9)YHQR>2`
M9R;?[=OZ/_K5BJ_6G.?U3J>-T_".]K-OIGLZZ\`M?_5HQW;_`/KEJ[#!PZ<'
M$IQ*1%=#`QOB8_.=_*?])R"7`^O7]"P__#'_`*+M6K]7O^0L#_PO7_U(65]>
MOZ%A_P#AC_T7:M7ZO?\`(6!_X7K_`.I"2GG?K3U#*ZCU(=#P_=6'-98P&!;:
MX>ILM</^TV/7[[?_`%$M7!^IO2:*@,MIS+OSGO):WX5TL=L8S_/?_P`(L7HY
M:WZYVBWZ1NRPW^L27-_\!W+N$E/*];^IN-]F??TMKFV5C<<4DN:\#7]%OW65
M7_Z+:[9_Y]5CZG]:MS\=^)DO-M^,&N9:[Z3ZG?0<_P#>MK<W99_UM=$N'^J!
M:[ZPY#J/YDUWEL<;#<STDE/_T=[ZS$?\Z\;4?]I/_/SUVZQLC*Z?9DFR[I-]
MUU3MK;CBAY]CCL=7:[W;-WOJ1OVXW_N#F_\`;!_O1X)=EO$.[S7U)(_;61!'
M\S9_Y^:NX6)1F=.QK#9C=(R*;'"'/KQ0UQ!.[:7,C\Y6/VXW_N#F_P#;!_O2
MX)=D\0>:Z>1_SY>)U^T9'_GIRW/KAT=W5NCOJK$VTN%M<:F6_NA.W,Z<S(^U
M,Z1D-R"2XW#%`?+AM<[U/I^YJL?MQO\`W!S?^V#_`'H@3!!&A&H03$@@Z@[O
MG_U6^L=OU:RWXO4&.^P93@ZPM!<:[!^C^TU`?SU3V-:W(K9^F_1_0^G6O2<+
MJ6!U"H78.17DUD3NK<'1/9T?0=_67/\`4\3I?42Y[NG9M5C]7.;CRUQ_>?4[
MV.61_P`T^EE^]V%;8?Y>#9_Z+R*VJ69CD/%*)C/KPU*,O\'TL<`8>D2$H].+
M20>RS>M]-PK!1=>UV4[^;Q*OTE[_`/B\:K?<[^OLV,_/7/=4^J?_`#@SAU-X
M94+&M8]A<20UOT6O=274WV:^_8_TV?S7K7(O3<3I^`PULP,H5N^E51B"BMT?
MZ5M/Z6__`*_;8M<=;8T!K<#-`&@`H,`?>F`2B;A8\;HKSPD5*CX4Z&/0S'HK
MHKT94T,;\`(69]:.FG/Z4_TV[LC&/K41R2T>^O\`Z[5O9_71/VXW_N#F_P#;
M!_O2_;C?^X.;_P!L'^],X)=EW$'GOJ1T]M^39U,B:J!Z='F]XW6V?V*G-9_U
MVU=HL7#S\3!H&/B]-S:Z@Y[PT4.YL<ZU_?\`?>C_`+<;_P!P<W_M@_WI<$NR
MN(.7]>R!A8<F/UC_`-%VK6^KW_(6!_X7K_ZD(&1U'#RFM;E=*R;VM.YHLQMX
M!C;N;OW>*G5U>FFMM573LRNM@#6,;CD-`'#6M;]%+@EV5Q!QOK5T;*IR_P!M
M8`=(+7WBL2^M]>E>4QG^$KV#9D,_]%^LCX'UYPK*6_;:GUVQJ^D>I4[^4S:?
M59N_<>W_`*X]:G[<;_W!S?\`M@_WK/RF=$R[#;?T7)=8[5SQCEKB?Y3JW-W(
M\$NR.(=VAUGZWG+J.#TRNQAR/8;7#]*X'1U>+0S?9O?_`*3_``?_`$UJ_57H
M=G2\5]N2`W+R=N^L016QL^E1N'TG>[?;M_/_`.+385_2\"3A]'R:7'0O;C'<
M1YV?35VKK+;+65_8LQF]P;N=20T3^<]T^UB'#+LGB#__TN[^R=5N^LK[Q?93
M@4,J(822RV6Y+;J653Z+?TC\:Y^1M^T?H?1_FK$;J@ZH>I=.&"XLJW7?:7.:
M75;?3_1>JQKZG;O5_FO>OFE))3],]"^W#I%)ZCO.6-_K;Q[IWOX;[G;-O\U_
MP:J=(RNM.SC9GX]E>+U!ANI8X@G&<QVQF+<QK?T/VC#^SW/_`$UOZ\S._P"Z
MZ^<4DE/T9UYO53U/`?B&]N+7KDNH+C$W8HG[.W]'E[J?7JN9=_1\:R[+Q_5O
MI]%7>O?M!W3G4]->^K+O?757D,8+/2#WM%N2ZM\,<RBKU+%\S))*?H_I&3UR
M[J+[>H4.HQ\BG]%1H6T68[_2NWVM<?5=GNO]:C_NKC5_X3>GZUD]:&0/V90]
M[,%@R;=0P9#B[9]@JW-L]3]5^U6?X/9E_L[]-Z?VA?-Z22GZ=ZH[/?TNY_3`
M1EN9-((`=K]+8V_]$W(]/=Z'VG]!]H]/[1^BWH71O0VV>A]LB&;OMOK3N@SZ
M?VSW_P#&^E^@7S.DDI^CJ1F_\Z,CUG7#&VL^SM+;S41Z;O5VV5/^P-_2_P#<
MJOU_W/\`!*UU2[)Q\O!R&BYV(Q]@RFTM=88=6[T7/HJ:^ZQGJ_Z)C]C_`/@U
M\SI)*?IOHK,P=(QFY^\91K'K;W`O!.L/?7[?4;_(4>AXUV/B6-O-SK#D9$?:
M+'V.]-MUK,7:;7/]GV5M.S_/?^D7S,DDI^FND_;=^?\`:_4C[6_[/ZG^BVU;
M/2_X+=ZBI8?K_M%_V_[;]K^U6^CL]3[)]G]_V7^:_4MGV?9Z_P!I_7/MWJ?X
M'[,OG)))3],]:=G.HKQ,%KQ;EO%5F0P[?0JC?D9`L<RQC;O3;Z>+[/Z595_@
MO51>E9&7D8-;\ZG[/EB69%?YOJ,)K>^D_G8]NWU<=_\`H7KYA224_2_U>MRK
M.EL;F"X953GLN]=I:XD/=$%P:VUFS9LMJ_1*KTXYX^L&6VP9-N.\6$67;F5U
M;75MIHJKG[%DUW,]2S'R,79D55_H^H_I[-Z^<DDE/__9_^T7%%!H;W1O<VAO
M<"`S+C``.$))300$```````/'`%:``,;)4<<`@```H/%`#A"24T$)0``````
M$)U=B?^HGA5U!L@`EG\8W(PX0DE-!#H``````.4````0`````0``````"W!R
M:6YT3W5T<'5T````!0````!0<W138F]O;`$`````26YT965N=6T`````26YT
M90````!#;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`````"W!R:6YT97).
M86UE5$585`````$```````]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0`'(`
M;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P`````0````!";'1N
M96YU;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+`#A"24T$.P`````"
M+0```!`````!```````2<')I;G1/=71P=71/<'1I;VYS````%P````!#<'1N
M8F]O;```````0VQB<F)O;VP``````%)G<TUB;V]L``````!#<FY#8F]O;```
M````0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V8F]O;```````16UL
M1&)O;VP``````$EN=')B;V]L``````!"8VMG3V)J8P````$```````!21T)#
M`````P````!29"`@9&]U8D!OX````````````$=R;B!D;W5B0&_@````````
M````0FP@(&1O=6)`;^````````````!"<F1456YT1B-2;'0`````````````
M``!";&0@56YT1B-2;'0```````````````!2<VQT56YT1B-0>&Q`<L``````
M``````IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`````4&=0<P````!0
M9U!#`````$QE9G15;G1&(U)L=````````````````%1O<"!5;G1&(U)L=```
M`````````````%-C;"!5;G1&(U!R8T!9````````````$&-R;W!7:&5N4')I
M;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`````````#&-R;W!2
M96-T3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L;VYG``````````MC
M<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``````$`$L`````0`"`2P````!
M``(X0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X
M0DE-!!D```````0````>.$))30/S```````)```````````!`#A"24TG$```
M````"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`
M+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`+0``
M``8```````$X0DE-`_@``````'```/____________________________\#
MZ`````#_____________________________`^@`````________________
M_____________P/H`````/____________________________\#Z```.$))
M300(```````0`````0```D````)``````#A"24T$'@``````!``````X0DE-
M!!H``````TD````&``````````````!2````Z0````H`10!X`&@`:0!B`&D`
M=``@`#D`.0````$``````````````````````````0``````````````Z0``
M`%(``````````````````````0`````````````````````````0`````0``
M`````&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`%(`````4F=H=&QO;F<```#I````!G-L:6-E<U9L3',````!3V)J8P````$`
M``````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P241L
M;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA=71O
M1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG(```
M``9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````
M``````!,969T;&]N9P``````````0G1O;6QO;F<```!2`````%)G:'1L;VYG
M````Z0````-U<FQ415A4`````0```````&YU;&Q415A4`````0```````$US
M9V5415A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E>'1)
M<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L:6=N
M96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI
M9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G0V]L
M;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O
M<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T
M;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$
M*```````#`````(_\````````#A"24T$%```````!`````(X0DE-!`P`````
M#B$````!````H````#@```'@``!I````#@4`&``!_]C_[0`,061O8F5?0TT`
M`?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3
M$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+
M#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#/_``!$(`#@`H`,!(@`"$0$#$0'_W0`$``K_Q`$_
M```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!````````
M``$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@`,`P$``A$#$0`_`.A^L#_K,.N.&(<D-EGV(4SZ)$"?5C]!_/;_`%_M
M7^"_X-=FV8&[GO'$JCE=<Z5AY;<+)O%>0_9MKVN,^H[TZO<UI;[GA7TE*26=
MB_6#H^9997CY+7.I8ZRV0Y@:QAVO>Y]C6,VL51_URZ$U^UMEEC?](RIY9]^W
MW?V$E.XDJ^%G8>?0,C#M;=43&YO8CECVGW,?_(>K""E))ED9?UKZ#BW.QSD^
MO?7(?3BL?D.:1H66_9&7>D__`(W8G1C*6D03Y()`W-.PDN<9]?\`ZM>IZ5]M
MV*_L+Z+6?]\]O]M;N+EXN92W(Q+F9%+OHV5N#VG^TR4I0E'YHF/F%"43L04R
M2I]0ZMT_IOIG-M]$7$BLEKG`EHW.;[&N_-1L7*Q\S'KRL9XMIM&YCQ.H^::E
M,DDLZKZP=(MS?L%60'Y1>ZOTPUY]S)]0;MFSV;'?G)*<SZXNZNUF-]B-XQI=
MZYQMV_=[?1W^A^F]+^<^A_A/YQ:?U?/4#TC'/4MWVJ#N]3Z>W<[T?6C_``OI
M;/4_Z?O1^H=4P>FL99FVBEECMC"0XRZ"_;[&N_-:BXV13E8]>30[?3<T/K?!
M$M=JTPZ'(J2I)B0!),`<E8^1];NA4N+&WF]P,'T&.L;_`-NM'I._ST%.RDLS
M`^L71\^P4T9`%SN*K`:WG^HVT-]3_K:TTE/_T-[ZS?\`BJQO_03_`,_/7;KB
M/K-_XJL;_P!!/_/SUVZ2GS7I.`_J?4!@![JZK7/=D.;_`*.M^_@^W^=]/T]_
MY_Z3\Q=B_P"J/0'5&L8Y8XB!:U[_`%`?W_4<YVYW]=8'U*'^6LCRHL_&YB[A
M)3P_U7?;@?6.W`<[<+/5IMC0.=0=U-VW][TM_P#GKK>J=3Q>E8%N?F.+:*0"
M[:-SB20QE;&#Z3['N:QBY/`_\7+_`/C\C_STY%_QG6/'2\*H?0?E!S_[%=A8
M/\[W)^*`G.,3U*S)+AA*78-S!ZUB_6RJVG$%M+*"!E8]PV2U^[TG6.Q['>O3
M9L?^KUW5_P#=G]#^CMTZN@83*FTO+WUL$,J#O2J:/"O'QO1I8W^PL+_%IC5L
MZ/D9(,V7Y#FO\A6`Q@78)9@(SE&-\,3L58R3",C\Q'1P>H_5#IV92YC"YA[-
M>2]D_!Y+V?UJWK@2_JOU/ZV[[/(X=903[+ZP?YNW\UUG^@R=OJ,_[=J7K:\Z
M_P`95]#NJX5##^FHI>ZZ.S7N;Z+3_P!M6N4O*DF?MG6$@>*/3S8^9`$.,:3B
M1PR_8]?U*BGZP=`%F*9]>MN3AN.AWQZE6[]W?_-6?UUD_4;J4B[IKY'_`&HH
M!Y`)VY-7_6[??_UUZT?J5797]5>G-LT=Z6X`_NN<Y[/^@YJP>NU6="^L3.H4
M-/I6..2P#O\`F9U']MK_`%?^O?R%!(`2D!J`2&:)L`G2P]3U[J7[-Z7=DM(]
M8CTZ`>]C_;7_`)G\X_\`D,6']1^FP+>I62>:,<GD@&<FW^W;^C_ZU8JOUISG
M]4ZGC=/PCO:S;Z9[.NO`+7_U:,=V_P#ZY:NPP<.G!Q*<2D170P,;XF/SG?RG
M_2<@EP/KU_0L/_PQ_P"B[5J_5[_D+`_\+U_]2%E?7K^A8?\`X8_]%VK5^KW_
M`"%@?^%Z_P#J0DIYWZT]0RNH]2'0\/W5AS66,!@6VN'J;+7#_M-CU^^W_P!1
M+5P?J;TFBH#+:<R[\Y[R6M^%=+';&,_SW_\`"+%Z.6M^N=HM^D;LL-_K$ES?
M_`=R[A)3RO6_J;C?9GW]+:YME8W'%)+FO`U_1;]UE5_^BVNV?^?58^I_6K<_
M'?B9+S;?C!KF6N^D^IWT'/\`WK:W-V6?];71+A_J@6N^L.0ZC^9-=Y;'&PW,
M]))3_]'>^LQ'_.O&U'_:3_S\]=NL;(RNGV9)LNZ3?==4[:VXXH>?8X['5VN]
MVS=[ZD;]N-_[@YO_`&P?[T>"79;Q#N\U]22/VUD01_,V?^?FKN%B49G3L:PV
M8W2,BFQPASZ\4-<03NVES(_.5C]N-_[@YO\`VP?[TN"79/$'FNGD?\^7B=?M
M&1_YZ<MSZX='=U;H[ZJQ-M+A;7&IEO[H3MS.G,R/M3.D9#<@DN-PQ0'RX;7.
M]3Z?N:K'[<;_`-P<W_M@_P!Z($P01H1J$$Q((.H.[Y_]5OK';]6LM^+U!COL
M&4X.L+07&NP?H_M-0'\]4]C6MR*V?IOT?T/IUKTG"ZE@=0J%V#D5Y-9$[JW!
MT3V='T'?UES_`%/$Z7U$N>[IV;58_5SFX\M<?WGU.]CED?\`-/I9?O=A6V'^
M7@V?^B\BMJEF8Y#Q2B8SZ\-2C+_!]+'`&'I$A*/3BTD'LLWK?3<*P477M=E.
M_F\2K])>_P#XO&JWW._K[-C/SUSW5/JG_P`X,X=3>&5"QK6/87$D-;]%KW4E
MU-]FOOV/]-G\UZUR+TW$Z?@,-;,#*%;OI548@HK='^E;3^EO_P"OVV+7'6V-
M`:W`S0!H`*#`'WI@$HFX6/&Z*\\)%2H^%.ACT,QZ*Z*]&5-#&_`"%F?6CIIS
M^E/]-N[(QCZU$<DM'OK_`.NU;V?UT3]N-_[@YO\`VP?[TOVXW_N#F_\`;!_O
M3."79=Q!Y[ZD=/;?DV=3(FJ@>G1YO>-UMG]BIS6?]=M7:+%P\_$P:!CXO3<V
MNH.>\-%#N;'.M?W_`'WH_P"W&_\`<'-_[8/]Z7!+LKB#E_7L@86')C]8_P#1
M=JUOJ]_R%@?^%Z_^I"!D=1P\IK6Y72LF]K3N:+,;>`8V[F[]WBIU=7IIK;55
MT[,KK8`UC&XY#0!PUK6_12X)=E<0<;ZU=&RJ<O\`;6`'2"U]XK$OK?7I7E,9
M_A*]@V9#/_1?K(^!]><*REOVVI]=L:OI'J5._E,VGU6;OW'M_P"N/6I^W&_]
MP<W_`+8/]ZS\IG1,NPVW]%R76.U<\8Y:XG^4ZMS=R/!+LCB'=H=9^MYRZC@]
M,KL8<CV&UP_2N!T=7BT,WV;W_P"D_P`'_P!-:OU5Z'9TO%?;D@-R\G;OK$$5
ML;/I4;A])WNWV[?S_P#BTV%?TO`DX?1\FEQT+VXQW$>=GTU=JZRVRUE?V+,9
MO<&[G4D-$_G/=/M8APR[)X@__]+N_LG5;OK*^\7V4X%#*B&$DLMEN2VZEE4^
MBW](_&N?D;?M'Z'T?YJQ&ZH.J'J73A@N+*MUWVESFEU6WT_T7JL:^IV[U?YK
MWKYI224_3/0OMPZ12>H[SEC?ZV\>Z=[^&^YVS;_-?\&JG2,KK3LXV9^/97B]
M08;J6.()QG,=L9BW,:W]#]HP_L]S_P!-;^O,SO\`NNOG%))3]&=>;U4]3P'X
MAO;BUZY+J"XQ-V*)^SM_1Y>ZGUZKF7?T?&LNR\?U;Z?15WKW[0=TYU/37OJR
M[WUU5Y#&"ST@][1;DNK?#',HJ]2Q?,R22GZ/Z1D]<NZB^WJ%#J,?(I_14:%M
M%F._TKM]K7'U79[K_6H_[JXU?^$WI^M9/6AD#]F4/>S!8,FW4,&0XNV?8*MS
M;/4_5?M5G^#V9?[._3>G]H7S>DDI^G>J.SW]+N?TP$9;F32"`':_2V-O_1-R
M/3W>A]I_0?:/3^T?HMZ%T;T-MGH?;(AF[[;ZT[H,^G]L]_\`QOI?H%\SI)*?
MHZD9O_.C(]9UPQMK/L[2V\U$>F[U=ME3_L#?TO\`W*K]?]S_``2M=4NR<?+P
M<AHN=B,?8,IM+76&'5N]%SZ*FONL9ZO^B8_8_P#X-?,Z22GZ;Z*S,'2,9N?O
M&4:QZV]P+P3K#WU^WU&_R%'H>-=CXEC;S<ZPY&1'VBQ]CO3;=:S%VFUS_9]E
M;3L_SW_I%\S))*?IKI/VW?G_`&OU(^UO^S^I_HMM6STO^"W>HJ6'Z_[1?]O^
MV_:_M5OH[/4^R?9_?]E_FOU+9]GV>O\`:?US[=ZG^!^S+YR224_3/6G9SJ*\
M3!:\6Y;Q59D,.WT*HWY&0+',L8V[TV^GB^S^E65?X+U47I61EY&#6_.I^SY8
MEF17^;ZC":WOI/YV/;M]7'?_`*%Z^84DE/TO]7K<JSI;&Y@N&54Y[+O7:6N)
M#W1!<&MM9LV;+:OT2J]..>/K!EML&3;CO%A%EVYE=6UU;::*JY^Q9-=S/4LQ
M\C%V9%5?Z/J/Z>S>OG)))3__V0`X0DE-!"$``````%4````!`0````\`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P`"``0P!3`#8````!`#A"24T$!@``````!P`(````
M`0$`_^$.$6AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T
M(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@
M/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB
M061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V
M+3$T.C4V.C(W("`@("`@("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&AO
M=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X
M;7`Z0W)E871E1&%T93TB,C`Q-"TP,BTR-E0P.3HP-3HR,BLP-3HS,"(@>&UP
M.D-R96%T;W)4;V]L/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X
M;7`Z36]D:69Y1&%T93TB,C`Q-"TP,BTR-E0P.3HP-CHQ,BLP-3HS,"(@>&UP
M.DUE=&%D871A1&%T93TB,C`Q-"TP,BTR-E0P.3HP-CHQ,BLP-3HS,"(@<&1F
M.E!R;V1U8V5R/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7`N9&ED.C`Q03=#-34S.38Y144S,3$X-S`W.$8T
M1$(R,C<P-#!"(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C`Q03=#-34S
M.38Y144S,3$X-S`W.$8T1$(R,C<P-#!"(B!X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240](GAM<"YD:60Z,#%!-T,U-3,Y-CE%13,Q,3@W,#<X1C1$0C(R-S`T
M,$(B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D
M93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ
M(CX@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C
M=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]J
M<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS
M=&%N8V5)1#TB>&UP+FEI9#HP,4$W0S4U,SDV.45%,S$Q.#<P-SA&-$1",C(W
M,#0P0B(@<W1%=G0Z=VAE;CTB,C`Q-"TP,BTR-E0P.3HP-CHQ,BLP-3HS,"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN
M9&]W<RDB('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-
M.DAI<W1O<GD^(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(O/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z
M>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD
M/2)W(C\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!8
M65H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`````````````
M``$``/;6``$`````TRU(4"`@````````````````````````````````````
M```````````````````````````18W!R=````5`````S9&5S8P```80```!L
M=W1P=````?`````48FMP=````@0````4<EA96@```A@````49UA96@```BP`
M```48EA96@```D`````49&UN9````E0```!P9&UD9````L0```"(=G5E9```
M`TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C
M:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,
M=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O
M;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ````````````
M```2<U)'0B!)14,V,3DV-BTR+C$`````````````````````````````````
M`````````````````````````````````%A96B````````#S40`!`````1;,
M6%E:(`````````````````````!865H@````````;Z(``#CU```#D%A96B``
M``````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D97-C````````
M`!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@`````````````````````````````````````````````
M````````````````9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````
M`````````````````&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````
M``````````````````!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<
MG@````%865H@``````!,"58`4````%<?YVUE87,``````````0``````````
M``````````````*/`````G-I9R``````0U)4(&-U<G8````````$``````4`
M"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W
M`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`
MZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U
M`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"
M+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+
M`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$
M(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058
M!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&
MT0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN
M"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*
M5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<
M#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.
MM@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q
M$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44
M!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z
M%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:
M41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#
M'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74A
MH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67
M)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J
M`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"
M+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S
M?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,
M.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^
M(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`
M1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)
M\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G
M4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6
M]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)
M7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE
M/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO
M;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!T
MS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA
M?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%
MJX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYF
MCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67
MX)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'
MH;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K
M=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*
MM@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`
M<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LV
MR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76
MV-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3
MXMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCN
MM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG
M^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`4@#I`P$1
M``(1`0,1`?_=``0`'O_$`:(````&`@,!``````````````<(!@4$"0,*`@$`
M"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&
M"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*
M&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S
M=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BY
MNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%
M;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0E
MDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$
MU.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH
M^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`O7_F
MN_,_OW8'=V*Z)ZIWKG^J=N8'9F#W?F\[M:6.@W-O'+;CJ,BE)''G&@DJL?MW
M"TU`8VAIBC5%4[F5V5$0-!2:A3PZJS!2*CHSW\I'Y5]N_(/9':6S.W<Q5;UR
M_4V6VLN'W_6T\$65RV$W91Y*>/"[EJJ2.FIZ[-XF;$NT=1XEEJ*:9?*2RZF\
M0?,YZVK!A4=7`^Z=6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+7.D`
MVNPO^+BQN!_C[V!4@=>ZU"?D;_,.^6F[>^-^Y/:?;N\>J=N;0WQN';.T=B;4
MDH:/#XV@VIFZK%P/N>EJ:"?^]&8R4E&9ZP5FJ$B7Q1QI&H`\M6-`>M=;*'PI
M[LW)\B?C%U)V_O#'T^/W1NW;]4,^*&!J;%U^5P68R&WZO,XF!G<Q8[-R8TU,
M:@Z8_(46X`)LPI0GCUOHU'NG7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO__0W/ODU\).@_EF-O57;&`RB;BVM#/18+>.TLQ+MW=-#BJJ45%3@WR$<-3!
MD,-+4CRBGJH9DAE+/%H9F+-*U*UZTRAJ5Z$3X_?'#J/XQ;'.P>H-M#!8BIR$
MF8S-?5U4V4S^Y,U-%%!)E]PYJK+561K?MX$C2^F*&-`D:(HM[TS`\.O*ND4Z
M'3W7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ+'_`%/^
M\CWI1*?BBTC[1UYJC@*]=@W%_P#B;^[#2:Z'!ZT"3\2TZ[]ZZWU[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5>O<G\L#XE=X]EY'M7=NU=RXO<FX*Q
M,ANZDV?NS(;;P6\ZX!4GK=P8RE1Q][7QH%J9Z-Z2:HMJ=BY9C=2!D\>O='JV
MKM7;FQ]N8/9^T,+CMN[7VUBZ/"X'!8FG2DQV*Q6/A6GHZ.D@C`5(H8E`YNQ-
MR222??F;4!CKW2@]TZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T=PW
MYD?._8WPQK>NZ+>6Q-Z[R/8L6Y9<?+M%\"JXW^[(Q1J%R"YG)X]B:O\`BR>+
MQAQZ&U6XNTJ@BO56?20*="?\3/D]MGY<=4-VSM/;.X]I8E=U[@VG_"MT-C'R
M9JMO/2I458.)K*ZD^UJ#5#Q_N:[`W`]^90!4'K:MJ%:=&(S63CPN'RV9FBDG
MAQ.,K\G+!#I\TT=!2RU3Q1:RJ>218B%N0+GGW4"O5NJH>C/YO74O>_;'774F
M`ZA[5PV7[&S?\#Q^5R\NT'Q>,E&/KLDU1D!09^JK#`D%`X/CC<AOK]+^[JH8
M5ZJ6H:4ZA_)3^<!TKU!N3+[&ZJVSD>\]TX.JJ<;FLOB<Q1X'KO$Y:ENDM!'N
MF6#(S[CJ:292M0,?32TZ%2OGU`@;\/\`;U0R`5H.BL[;_GG;@CR"_P!]?C;0
MRX9G02OL[L5FRT$;,H,B4^?V_1T-6R"Y">>'6>-0]^T?9_/K7B_T>KF_C;\H
M>H?E7L9]\=2YV:MAQ]4F-W/MO+T_\,W9L[+O&9H\9N3#-)*U+)40J7@FC>6E
MJ4!,,KZ6TT(I6G3H-0#3HP_NO6^O>_=>ZX:Q:_!]14`&Y-C;CCGW4LR*?$2D
MF:*#4D>1^5?Y>O6SVTU&G5>OR)_F>_%;X[[IR'6<V9WCW9W7C017=(?'+9>9
M[E['P\G[JI'NRDVQ%)@MBLTD8!7-5]!(`P8*5Y]C_ESVWYGYBLSNR6\5IL8I
MJN;J18(%Q7+-W'[45AZTZ!V^<]\N;`S17%S)<70_T&V0SSFGQ4B0Y(X`%@2<
M<>JW>P/YT'R_HC)4]?\`\J7M^#&(K2)4=I=H[7P.8G@+WBE.V=N8_.U%(S(>
M8S/(^K@_3V-(/:+DV@-S[M[6?6E3^PEP"*\#05'EGH'W'N1S,/\`<7V]N2"*
M@F91@Y%5T`AJ?$M30XJ:=`GA/^%)U;M'.18#Y$_!;L?8$YF1:B;:V^J&NK:6
M(.$G,.$WEM[9XRTL9YM3UK!@.+^Q*OW=DW"W:;EKGVRO'IA5B="3Y"NIAGA6
MG0;/OL^W3&+F7DRZLP#EC(K"GF::1P&>/5SOQ(_F<_#;YK2+A^E>U*5-_K!)
M55/4^_*238_9L%/$&::>FVSEV`SM/"B%GEQD];"BB[,!8^X@YP]NN<N1I-',
M&R21I_$O<O[1C'SI7RKU*?+//O*O.$`GV'=HY2?PGM;]AX_E7H_>L#5>P"_D
MG_>_R/8'5D>NAJL.(X$="^K`]ZT7R->/5<?RP_F0[+^(O9>-ZYWUU#V9GAGM
ML4FZMN[IVY+M8X+-44E7-C\C24W\3S5#61Y'"UL2K41.@LDT;J2KCW8`5`]>
MK=&&^*/REV+\N.KE[/V-CLS@8:;<.8VOF]M;C;'C.X+,8B2-O%6KC*RMI6AR
M%!40U5/(CE7BE'T8,!<I05!Z]T9GVWU[KHFPO^/S<@`#\DD_@#WL"IIUHF@Z
MIFWA_.MZ)VUNW<^U\1U/VWO.#`;GR6UL;G=OC:/\.W754&2?#PU>!AK,_!6R
M4F4R*:*8R1HT@*M8!A[NRA17JBR:FH!U<+@<A69;!X;*9#$U6!K\EB\?7UF#
MKI()J[#559215$^*K9:5Y*:2LQ\LABE,;-&70Z218FA%.G.JM_D9_-HZG^-_
M;N_.GMQ=4=G[DS.PAC&K\KMZ7:0QE>,I@J'/1_8KDL[15G[5/7*C:XUO(IM<
M6/NP`)*^G7NK.=G;EI]Y[2VKN^CI:BBI-U[:P>YJ6DJS$:JDI\[C*7)PTM28
M6DA-13Q505RC,NH&Q(Y]Z9=/GU[I2>Z]>Z!+O+Y%=.?&_:1WIW)O;%[/Q,KR
MP8JEG:6LSNXJZ)!(<=MO`44<^6S=;9EU+!$RQ!@TC(OJ]V52W52P7CU3WV!_
M/*V[3UU12]4?'[<6>Q\4K+2Y[L#=6/VD*R$<+,F`P]%N.OIK_73--&UOJ`?=
M]`\NF_%`_">FO97\\VC:MAI^S/CGE*+'RS1BHRVP-\46<J*6(DZG_@>?Q>!>
MJ8#G2E6OT_-_?M'6_%KY=6]_'OY6=&_*'`39WI[>E+G9\>L1W!M>NBDP^\MK
MR36"QY_;5<(Z^D0L=*SH)*:1N(Y7L?=&6G3@8,*]&*]UZWU[W[KW7__2O6_G
MJ?\`%^^,/_4%VL/]<?[\S@_U'NJ</]7SZ:EXCHW?\F#_`+(T?_Q,?9G_`+E8
MSWI_A'5HN!^WJSO?7_'D;R_\-7</_NHK/;:^?V=.=:%&V<QG,!)B\GMFNRN,
MS\<3T.+JL%42T>9,^7ADQ+46,J:=DJ(:K*PUK4H*,&83%01?VY'\/2=_BIUL
MI?%C^3KTIMS8.W\W\D,?D-_]A97&TM=D-H4^8R>`V-LE*F".:#;='082HH*S
M,9'%K(8ZJKJ9VCDFU"*-44%MEM)X9ZN(ZC)Z<OE#_*$Z'S?7&Y<]\=L/D^M>
MSMOXBNRV!Q-+G<OF-I;MGH*>2K;;F6Q6;JLG)1S9=8O#!54LD+03,K,'74/>
M@_H,]>,8\CU4#_+*[ERO4?S!ZN6FFJ:3;_;M:.IMY8B1A'#,<TL[;;FKH[Z#
M68#=%/$B.?4@GE3Z.WO074=7KUH-I(3T\^MQI00`#R0+>Z$4)'3PX=`IW?\`
M([HWXU[6BWKWWVKL;J?:]36G'4&5WKGZ7$+E:]5#O0XBDD+5V7K(XCK>*FBE
M=$]1`7GV9[/L>^<P7DEILFUR7+I'J.@$T/H?0?.N>`!Z+=RWC;-E@^IWB]CM
MX2:`L>/G]OVTK3SZ*IV)W)M_Y1[#P8^/_:7]\^H][T]0D^9Z$W=%%O'L.I20
MQ5VSX]^8MY:WI_;-"'7^,5D2P[BGUBGI#2+KG=Y(&Y+O5&^[0Z;ZS`K'*K,E
M>/PL!K%:!1A1QH2`.M6TD?,]H9=FW2)K<K76K#A]OX?GY^N,=)KKGX"U.,VS
M3[7GSN'Z2V#>2<]5=!8J':&+DDG8O-4[GW)#_OX=X9RK8WJ:[(U594U$A+/(
M6)/M+O>Z[IS)>1[GS#N=S=[LG]G)(YTQJ/A185I%1115!7@.E.UV-KLBE-JL
M[>U!/<L48".WXG<M60LQJQ(<`DF@'2WJ/Y9OQ@JZ5HJO#[FJJMR&?)U&Y*V6
MN9_RWE<D@G_>_97X%L<FRM2?/]+]OXO/I?XK?P+7[!T3#Y(?R==M;MVODX>N
M\^^?IA32,NR=](,G25'I:Z8ZOE+SX^K"6"21M$P8?7\>SO:=[W?89A+L>XS0
M)4=NLG^?^JG11NVT[9OT!CWRPAG>A[M`'EZ9_P`/6H/\J?C#OCXH]DT7HW)M
MIL7G5FV]EH:S(8K=NPMUT#_=TO\`#MPT<E+7P2QJGEQU?!(DCA2I)9;'.'VG
M]RX/<7E[<-CW_P`-M[MFHT<E)#+'^,U(&FJU]>L./<_V[N>1M[VW>-DD==CN
M`"LD8\-8I`>P%03J[J>8ZVO_`.2)_-(W)\N=N9GXW?(;+P93Y$=7[?ASNW]\
M3+3T51W3UK3U$&.DS.1I(A%3-O\`VA4U$$.7,"A:V&:*K"*QG(Q\]Z?:].3=
MQBYBV*$CER[8Z5H:1%LZ-5<CS!-*'%*$`3C[2>XAYNLY=BW><'F"T`U&N9`/
MQT\C7CQQD\#4Y'\V3X[2=U?&JOWKM_&O6[\Z*GJ>P,0E-`TU;D]J+3&#?N"@
M5`6<S82,5J`W_>H5L+GW!JY(^1ZF<F@)ZJ7_`)0'R'BZN^1,W567R*Q[+^0-
M!#CL8SR,**#L?`4U16[8G0:&_=W%B!4T(/I#RK3@GZ>W"*@CIM9*D"G6U8IN
M+_3DBW^MQS[8Z=Z(%_,J^1,GQY^+6\JW"5ZT>_>Q_P#C&6PV1T^YILGN6FGB
MR^=AC)$A7;NWDJ:D.OZ)UB^EQ[NG'JKFBGJA'^5;\<E[N^3N"SN6H#4=?]"4
MU#O[-FHC\U+D=UK(]/U_@I6E26.>2/(PR9.9'Y9*$7_7[<;AGIF/XZ];=8!`
MY-S^3:U_]A[8Z4=::?\`-%_[+:^1O_+/:/\`[[G`>W%^)NM=;;/1O_,E>G?_
M`!%77W_O)XCWY^`ZV.F7Y&=Z;2^-O3>]^Y-YEI<7M'&&6BQ,,T4-=N//ULJ4
M.W]M8WR'U5V:RT\4*D*_B0M*PTHUJJNKJK-I'#K4,)^1/\PWY)1>4C=?:&]'
MJ'I:>>>J@V/U3L6DF#5"1&TXP6R]O1SJKM&K5>1K''^>J)@/=LH?6O3?]K\J
M=7S]-_R:OC+LW"T;]M5>ZNY]WO"C96MKLQ7[4VE'4D`O!A-L[=JJ26*C@<$(
MU755<S@!BP)L-ZQZ=6$?SZ?.TOY.GQ*WGAZN+8%+NWIO<GA/\.S>V=P9'/XN
M&<6*G)[7W35Y*BR5*Q'K2*6DF/\`9E7W[Q!Z=>\(>1ZH`[)ZV^0W\OCY"XP)
MF)=K=A;;OGMA]A[=2H_NOV%M9ZD1U.F">XR6$K[?;YC#U8D\#MI((,,S:H6-
M:T/6JZ,4K7K:Z^'WR:P'RPZ-VQVMBZ6#$9N9ZC`;\VQ#4/4?W6WOB`D>9Q<<
MLH$LV/GU)544AN9*.>,DZM0%7%#U=6J*]&C]UZMU_].];^>I_P`7[XP_]0?:
MW_RF>ZIP_P!7SZ:EXCHWG\F#_LC1O_$Q]F?^Y>,]Z?X1U:+@?MZL[WU_QY&\
MO_#5W#_[J*SVVOG]G3G6E#\+MMT6[_E/\8]N9*".JQM;VWM"KKZ:4!HIZ?"3
MS9X1.K`JRM48M+C^@]WC^'\^FBFHZJ];PR_GF_J;Z_\`!CQ_OOQ[T_Q=.`4Z
MY>]+\0ZWUHZ;)3^#_+W::8UC3?POY7T"4+(`#`(.X&2*RBR^E.+?3VXGPKTG
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MD*3\"D$@*>-!7_!ULN#@`?6P^O\`7WCYGSX]38!0`=>]^ZWUX_0_ZWO8!)H#
M0GK1(`)/`=43_P`]CXY;:W]\/.Q^XXZ"GI]T];8>#,3UZ11JU11T.1IGI))V
M"AGDIG<JIO<B2WT]R)[0;J=H]RN4V5>Z[E:*2GFJ@DD@>M"/D#\N@%[H6$>[
M>W?-5M+-V6UMX\9H*AO(#T`)!KQJ.M2S^6WVAE.G_GY\0]\XJKGHS/W-MW9&
M:6!FC-;M3LF.HV5N*@D8$++#+39I92AX+0*?P/>:WN5MJ;K[=\SV$LGB6R)+
M=1D@5B,8+JB^HQ2IS3K$/VSW!MK]P>5KE8_#N9XXX)*$TDUT4L?GFM.OI255
M/!54U12U4$5535$$M/44T\:2PU%/-&8YH)HI`R2131L592""#8^^<PPU/GUG
MUQ'6E-\N.D\_\2?E%O#9>V9*G#T^WMR8SL[IS,J7C,6W*_)G/;5DII[1B23;
M.9I)<;+I-KT@!%F%W2*@CIH1@,&KPZVYOC+W?B/D3T/UOW%A_$C;PV]33YG'
M1O&7Q&Z:%WQFZ,-*BN3$^-SM'41@/9C&%8@!A[KH!/'IPD@=:U?\VGY$KV_\
MF:_8N+KFFV)\>Z"LVG3I#(\E/6[^KU@K=]Y,0BZFHQHCIL4A`)+4TMOU>]$:
M>X>739.LE.KP_P"6;\<F^/'QBVLF<H!2]A]IE.S-^ET45-'4YREA;;NWIG'J
M";>VX((3&UF2I:8D`D^],U0!3/5E73Y]6%^Z=7ZTTOYHO_9;7R-_Y9[1_P#?
M<X#VXOQ-U[K;9Z-_YDKT[_XBKK[_`-Y/$>_/P'7AU2[_`#R>P*ZGPOQ^ZHII
MY$QF8SFZNP<Y2K(0E9)MBBHL/M_6@X/V=5GJB12;C5:W(][3@1TU*<#[>A*_
MDG=38C"]%[\[HEIT?=/9&^LCMJ*ND@7S4>TMB&.CI*&FE:\D<-?G*JLJ)E!"
MR,L9-]*V\_#KT8XGJZSVUT[U[W[KW55?\X+J3&;]^).7W_\`:P'<G2.?PF]<
M1D&%JB/"Y3)T6VMVXV-_S!78W(I,RGTF6DB8_I'MU.!^WJC+J\^B$_R/M^UU
M!VOWCU<]01AMQ;)P&_Z:F<W49W;N7&WJR6G']AZC%9J$2?34(%_I[TWQ$?+K
MR+I%.MDKVWU?K__4O6_GJ?\`%^^,/_4'VM_\IGNJ</\`5\^FI>(Z-Y_)@_[(
MT;_Q,?9G_N7C/>G^$=6BX'[>K.]]?\>1O+_PU=P_^ZBL]MKY_9TYUIG?R]P#
M\ROBZ"H/_&0%:_\`B-NYPK_R2W(]WC^'\^JCK=:_XJ?]X)'NK_%U;KL>_)\0
MZ]UH[[<_[+!P7_BV5-_[^(^W%X+TP_\`:-UO#$A02?H+G^OT!/'^V]TKI+?M
M_ET\,]?,=^;N-R&+^9GRJI<F7-;4=X[[RWDD<O)+#F,DV1HZB[<LLM/4KIMQ
MQ[Z,>ULYO/;CDIQI:**"$,`>%.->L!O<E&L_</G$3JR&::9D(XD'@>MWO^2'
M+M>I_EJ?'#(;;-(:B?";AH]RBG*,]/N7#;KS6+RM)5%!J6HA>F!(;D:[_0CW
MA7[P1&S]S.8A+"562:1E/]$MJ6GR->LN/:N=+CV_Y>%N5.B%5/S8*`Q/SZMH
M]QQ\^I"Z][]U[KH_0_ZQ][7XA]O6F%5(]1U0Y_PH1[_I>I?@M/U)3)+-N7Y-
M;RQ?7=`RI:"CVQ@)J?>6]*Z68$!'%!C(:2)?J[U=_HI]SC]WKEAM]]QK*\F5
M/`VY9)14Y;4C+0^5:%B*>:@>9ZAOWSWX[-R'?VD<9\:^18*C\(%#7]ND9Q0G
MK4Z_EQ];U_:?SE^-6WJ&!YZ?`]DX3?>8,0)\.-VG,:^/R6!"+/D5A0?0DD_T
M/O)GW@WZ'EGVXW>ZO862XO"]K"@X,LH*!W\P:&IIBO6/GM+L+\P>X&QQV=PK
MQV4*SS,>(:.C%%\CPH*YZ^E0+@`'D@`$_P!387/^W]\]!5=()J0!_@ZSHXU]
M.J:OYROQX&_^E,/WU@:`R;HZ+J9&W"\$:F?(]8;CGIZ?.)*P/EG3;.62FR"H
MH.B+SMP+^W0Q)'56)`)'5;/P"^=,7Q=ZD^26R<[5I*&VS6]C=*T%2[20U7:5
M5!#M^LVS21B*6$KEI9*/)N&*H8Z2H-]3"]^FO$Q0X/0#_`;H'(?*#Y4;0PNY
M?/F]M[;R,W<';V2J@TRY6FQN57(QT%9(6#/-O#>53#$XN6\'F^H7WIA537K2
M9<=;F2VTBW`_`M:P_H!Q8#\>V.E'7+W[KW6FE_-%_P"RVOD;_P`L]H_^^YP'
MMQ?B;KW6VST;_P`R5Z=_\15U]_[R>(]^?@.O#JD+^>;L^L6J^./8Z1.^,2;?
M6PZ^949DIJVMAQ.?Q*2O^A#6IC:H)?\`,9]^3_)TS**Z?7HPO\E3L7$Y[XQ[
MIZY%0%W!UGV9GY*ZCD91)_`M["+<."R"`G4U/45#5D(-OU4Y'U][?AU:(X('
M5QGMKISKWOW7NJS?YMO9&*V/\+M][<JIX/XQVOE=M=?8&A:55J:EZG,TF<S5
M3##RTD..P.%J))#;2MU!(++=U.'5';3U6;_)#VA6Y+OCN;?G@D.(VKUAB-JM
M5!6\(S6[-R1Y.*F+\J9!C=NNY'U`93]/>F^(_9UY&+"O6S)[;ZOU_]6];^>I
M_P`7[XP_]0?:W_RF>ZIP_P!7SZ:EXCHWG\F#_LC1O_$Q]F?^Y>,]Z?X1U:+@
M?MZL[WU_QY&\O_#5W#_[J*SVVOG]G3G6F=_+V_[++^+O_A_K_P"\YG?=XOA_
M/JHZW6O^*G_>S[J_Q=6Z['OR?$.O=:.^W/\`LL'!?^+94W_OXC[<7@O3#_VC
M=;PQ-OP2+\V%^.?QS[;;XCZ=/#AUI`?SNOA7N39/R`SO;^U,/45E%N:F;*5\
M%'!JDR^+0EQ64:HI^XRV%U,DT0N[T]BMROO)/V(]R;+8A+RAO=R?!GDU1DGX
M0>`!X4'4`^]7MW>;T8.;MG@#RV\061?)B.)H,U/V])+^2W_--P'PHW-G>B>^
M,A-1_&OM/<2[BQF]#%55<72W8]=!3X_(Y/,4,"R3IU_NV*F@_B4L:,^-KH!4
M%1#).5DCWP]KKWFV%.;^7;4R[I'$J:5H4D10=+8[@YK7C0Y&,$1W[.^Y-ERP
MTO+6^W(CV]Y&?4]0T;L<CS&@4I2E1@U-*'>/P.YL!NG`8O=.U\[A-Q[;S=%!
MDL-N'`9.BS&!R^.JD#TU=B\M05$]!7450ANDL4C(PY!]X27$<ME*UO?H8)T-
M'#@BC>8H<KGR:AZR^@GCNH8[BS83Q.*J4(-0>!!R#T]:_P#:E^E_I_TG[;UQ
M?[_7IVI_WTW3=D<M18G&UN7RU;0XG$XZBJ<AD<GDZF*AQN.H:2)YJJMKZ^J>
M*FI*2FA1GDDD9%1022`+^[1+/.ZP1P,+HG%!X@/R&FF3TPTFE#.9%^GI^*J$
M?,U_RTZI!_F#=7XO^9=UQM?&=1XN#L/KW9V>R59@=WSS28K$=@[@IT-#5Y#I
MBMTQU^?PV%"R0UFX("<-5M:"DDJ2'9!KLNZ;UR+=/N5O=-%N3``QUP`>`8#(
M)K736M#4]$6Y;5M'-MO]#=P"6Q`)#4S6GE4?Y./29_E>?RM:GXR[YJ^TMY;4
MAVU74]/X<;25U>V8SN0J/5X9LA6RDLM-2%RR(H5=7)N>?;?-?/G,_.C6YWV^
M+6\0Q&M=%?6A)->FN7.3.7.58Y%V;;PDSFID/QGY5%!3\NK^?8.Z%/3/N+!8
MC=.W\YMG/T462P6XL1DL%FL?.-4%=B<O1S4&1I)5')CJ*.H="/J0?=E^(=:(
MJ"#UHW?(3IK*_'7NKLCIC.%_]^)G9H\%D*A2O\4V5D(_XGM#.78DM'4X*>-)
M6!XFBD']D^W6-`3TWX2GS/6R9_*+^.\O4/QR3LO<>-:DWQWU64^\9EGB*U6,
MV'2PR4^PL4XEB26G-7032Y*102&:N6_*^VRQ*@$<>K*@7AU:[[IU?KWOW7NM
M-+^:+_V6U\C?^6>T?_?<X#VXOQ-U[K;9Z-_YDKT[_P"(JZ^_]Y/$>_/P'7AT
M'/R^^.6(^5/0N\NH<A50XO*Y**GS.R]P31/,FV]\8-FK-NY:2./UO2&;7352
M@%GHZB50+D>ZJU,=590PH>M3_IKMWN_X#?(G*5TVWI<-O3:<S[0[2ZQSDDM+
MBMX;;>=*C[5*Q`X:CG*BNP.7B66(:@UGB>6,V!+'/EU0_ITT^?KULJ=.?S//
MA[VYB*&>I[2Q/6&YIX4;(;,[1D7:>3QM3XT\\<>5K#_=W+4BRL1'/35;B11<
MJA.D;T#JZMJKT]=J?S)/AQU5BJFNK>Y]M;VR<<!DH]J=92IOK<.5<FR0TRXB
M5\51D_VGK*FGA4?5Q[]H7U/6F?33K6G^57RB[8^=7<N`FIMM904JUK[4Z2Z;
MV\S9G)4\F8FB$LM088XX\KO'<'@0UU2%6GI*:,(I$*,[7`ICJH&NI;K9I^`O
MQ33XE]"XK9V7>CK.Q]TUK[Q[/R=$R34S[FKZ>&&+`X^K"*]3B-JXZ&*B@<EA
M(\<DHMY2`T_'JZKI%.CM^Z=6Z__6VV_GG\":GYJ9#JVMI^TO]&XZX@W9$R#:
MB;F_BYW/_!+$Z\OBQ2"C&(_VO7Y/Q;EH,0,$=:90W'H8_A3\7I?B'TL>HY=[
M'?[G>>Y]V_Q\X-=O\;CEI910_P`/2OR(_P`D^V_7Y/5J^@M[T6J*'KRJ%K3H
MT6>QAS6"S6&$WVQR^)R6,%1H\OVYKZ.:E$_CU+Y/$9=6FXO:U_>@:=6ZI8^.
MW\GJNZ'[IZK[<E^01W0G6NX!G9,!_H\BQ?\`&;8VOQ_VPR"[EJS1"U:'U"*3
ME;6YN-J=(I44ZUU=X+VY_J?]L2;?7\V]Z))R>MCKQ-N;7_UOK[\#0@]>ZHLQ
MO\F:OQ_<=!VO_LQ)E2B[<B[1_@7^CB%#(L>\SNW^"???WG)4,/\`)S/X[@>O
M3^/=@Q`&1U0H"2QK7J],&XN1:_X/X]U)J:]7Z`GY`_'S8GR)V/5[/WG1CS*L
MLN#S<*@9'!Y!T(2II90-06]M2_0CWL,0RNG;,O!A@C[#Y=>!(5D/=$>*G*G[
M1UJ9_,/^37O3:F8RN>H]LY*LI)&DGCWOU]#%/%6(;CR;BVXZ?:3503AI$$4C
M`\DGW,')?OCS?R:\6VPF3<K!E`*$$NOR#5\N'#J,N</:+E/FN"6\&V>%N0)/
MZ1"`UXU%#6OV]$SZ.VW\[_B+D)\=\;/E9D.KL.]7]S4;)W!'F8=BSUFHZYJW
M96X\1N7:5--(6(=Z:&(M<W-_<BWONY[1\VRJ_-'(CO.!0Z3H8'\0+**\>.>H
M[V[VM]RN6P1R]S@L49X*PU``<`033`QPZLRVC\S/YM^X((*7<7S5^(6THIE6
M)LCB>BZ[?FYB2=+/38;$86BQKU8!N`X2*X'L"W>[>Q"/6VY;W;CP-QBGI_9U
MIY<:_/H<VFW^\3@BXWO;00./@C]O'\_+HT_5GQE[2^1F3QF<[UW[WU\U\E2U
MT&2I1\@8J+J3XE[9R$$JRP93'?''8ZXS$;]GHW4/`NX9*V$,JZH&]A_<O<-2
M9=OY)Y:CV"S*FLNC7<,*4*F9RS4(\@!QQT>6'(0N`FX\U\P-N%Z.$4A_04C-
M5B0*`:\#7TK7J]WJ_K!-B4"5&7R9W%NJ>E@I:O+&EIZ&BH:*GB6*EP>W<521
MQ46%P&.C7QT]/`B1H@```X]QHSR/(99)&9CY$X%>/YU\^AS$BPQ"%!VC]OYG
MH6?=>K]>]^Z]U[_7Y_U_>P:&O7NJH/G]\!9/E+V_\=-]8"EC@IZ'=%+LCO*H
M2:"EDJ>H(VJMS1UL2,$-;D:/(T<V-0`L_CRWT"1DBQ)84_;UKJU3'T-)C*&B
MQN/I8:+'XZEIZ&AHZ=%CIZ2BI(DIZ6F@C7TQQ001JJJ.`!;W4FI^76^I?O77
MNO>_=>ZI9^5'\H^N^2?>79/<<??G]SHNP%PZIMT=>Q9HXK^%;;Q^WV)R;;DH
M#5>?['R\Q)IU:>;7]V!H20>/6NK>MA[9;9>R=F[/:L_B)VEM/;NV#D/#]O\`
M?M@<11XMJS[?7*(!5?:Z]&IM.JUS:_OS,3CK?2L]UZ]T4CY2?"GHOY:X:DI^
MRL#4T6[,-334VV.R-KSQ8K>^WXY6:3[./(F">'+85IVU/05L<],26*JCMK]V
M#4\NJLH;CU2KV!_)"[LQU94?Z->W^NMY802DTL6]<7FMJ;@\1_2M0<53Y_#R
MO']&93&'^H0?3W;4WD1UY5"\.FO9/\D3Y!9&MA7?/:W5.R\,90*M]MT&X=VY
ML0W]34E-4TFW<49"/IKEL#^/?M34S3K3(&H3U<O\3_@'T/\`$F)LQM+'UV[N
MRZVC>BRO:6\FIZW<STLX3[G'8&GABBQNT\/.5]5/11H\HXFDEL"-:SUM5"X'
M1W5&D6!-K\7_`!_@/\![J26-3U;KOWKKW7__U]QO=6POGI5[HW#6;3^3?Q]V
M]M&NSM?)M+!9OXW;BS>:Q6$GF=\9B<IFXNZ\1!F<G24PTR5$=+3K,P+")/I[
M$EG?\H+;1+<['<RW`'<PG"@GY+X9I^WH+W-GS6]S,T&^6T=N3V*8=1I\R6'\
MNF0=;_S%C>WRN^-_I)!_YQ6W0""/J"#WU<>U`W+D?SY:O/\`LH_ZY=-?0<X?
M]-';?]DX_P"@^O?Z-_YBUP/]FN^-_(O_`-DK;H^E[?7_`$]6^ONQW+D<`'^K
M5Y_V4?\`7+K7T/-__31VO_9./^@^N7^C3^8O_P!Y6_&__P!)7W/_`/;Z]^.Y
M<C@D?U:O/^RC_KEU[Z#G#_IH[;_LG'_0?77^C;^8OJT_[-=\;[VO;_95MT?_
M`&^O=?WER030<MW?_91_URZW]!SA_P!-';?]DX_Z#Z\O6W\Q9@"/E=\;B#]"
M/BON>Q_]CU[V-RY'I_RK5Y_V4?\`7+K7T'-__31VW_9./^@^N#=<_P`Q-"H?
MY9?&M"\BQ('^+.YE+RL"RQJ&[\&IV`)`')'OPW'D@UIRW=T_YZ?^N76_H.;_
M`/IH[;_LG'_0?63_`$:?S%_^\K?C?_Z2MNC_`.WU[]^\N1_^F:O/^RC_`*Y=
M>^@YP_Z:.V_[)Q_T'UQ/6_\`,6`N?E=\;_U:?^R5MT?J^MO^9]?7CW[]Y<CT
MK_5J\_[*/^N76OH.;_\`IH[;_LG'_0?7!NL_YB4JF)_E9\;9%=26C?XJ;F97
M0FQ#JW?!!!O^?>AN7)29BY=O$-:U6XH:^O\`8G/Y=;%CS@"#_6.VK_S0'_0?
M2&S'Q=^8>X=9SG<?PURTDG^<FKOA;6U,[_Z\TW=LDG)_Q][_`'CR,?BY;O2?
M^>DBOVTB'7ELN<5-1S%:G[;8'_"W6#$_%7Y>8%D;#=O?#+&R16,<M+\*JN&9
M/S=)X^ZTE!_UC[HNX\DIPY=O?SN6/^&/J[V?.+D%N8+0'Y6P'^!^E]'U?_,/
MIXTAA^5/QJ@B4!8X8OBEN2.-0/HJ(G?`50/\/;IW7DH_'R]?,?4W-3_*$=-?
MNWFSA_6"T_[)Q_T'UT-@?S#6J9:-?EO\9VK((HYIZ1?BYN-JJ&&8LL4TM.O?
MIFCBD*D*Q`!L;?3W7]X\DTK_`%;N_P#LI_R>%U;Z#F^M/ZQ6U?\`GG'_`$'U
M(/6O\Q<<GY7?&\?Z_P`5]S__`&^_?OWER/\`],U>?]E'_7'K7T'.'_31VW_9
M./\`H/K`O7W\P]Y7@3Y:_&AYHS:2%/BYN1I8SQP\:]^%T^H^H'U]^.X\DBE>
M6[K_`+*?^N77OH>;^']8[:O_`#SC_H/K/_HU_F+_`/>5WQO_`/25MS__`&^O
M?OWER.<#EJ\K_P`]'_7+KWT'-_\`TT=M_P!DX_Z#ZZ'6W\Q<_3Y7?&[C_P`!
M7W/_`(C_`)_W_4>]#<N2,UY:N_\`LH_ZY=;^@YO_`.FCMO\`LG'_`$'UQ?KC
M^8I$C22?+#XV1QH-3O)\6-S(B@?4LS=]A5`_J?>_WER.>'+5Y7_GH_ZY=:^@
MYP_Z:.V_[)Q_T'UP3KS^8A(YCC^6GQID<(DA2/XM[D=A'(-4<A5>_"0D@Y4_
M0_CWX[CR0*5Y;N_RN?\`KEU[Z'F__IH[;_LG'_0?64]:_P`Q<`D_*[XWV`O_
M`-DK;H_'_E>O?OWER/\`],U>?]E'_7+KWT'.'_31VW_9./\`H/KW^C7^8N1<
M?*[XW\_^`K;H_P#M]>_?O+D?RY:O/^RC_KEU[Z#F_P#Z:.V_[)Q_T'U@DZ__
M`)A\4L$$ORV^-$4]49%I8)/BWN2.:I:%=<HIHG[\$DYC3EM`-AS[]^\>22"?
MZMW=/^>G_KEUOZ#F_`_K';9_Y=Q_T'UG'6O\Q<\_[-=\;^?_``%;='_V^O>A
MN7(_GRU=_P#91_URZ]]!SA_TT=M_V3C_`*#Z\>M?YBX%_P#9KOC?86O_`,XK
M;H_)L/\`FO7]?>SN7)'ERU=_]E'_`%RZ]]!SA_TT=M_V3C_H/KO_`$:_S%_^
M\KOC?_Z2MN?_`.WW[T-RY'\^6KS_`+*/^N76OH.</^FCMO\`LG'_`$'UU_HV
M_F+<?\Y7?&[F]O\`G%?<_P".#_S7K^OO?[RY'H#_`%:O/^RC_KEU[Z#F_P#Z
M:.V_[)Q_T'UW_HU_F+_]Y7?&_P#])6W/_P#;[]Z.Y<D>7+5W_P!E'_7+K?T'
M.'_316W_`&3C_H/K/B-@_P`P!<MC)LG\JOCED\/29O'KG<?COC)N.EK:O'T]
M73RY?$TU?_ITK$QF2J<?K2.5XI?`[J[1N!I/I+[DQXI$AY=NEG*FA-Q4`^1(
M\(5IZ5'5X+'FM9U:XYAMVM_,"``_/.OH].L?[5_R9[!^EO\`?/\`/H453_?P
M_E_FZ__0V2?YCO3FZ^__`)A?$CJK:VU^K=V2YWXV_-LS1=TU>_X-D[4J*BK^
M.N&QV_<-3[!05M5V#MNJRNO&EY\?-%$TS4M;23VE#0)!&F@J/\_7N&/\.>K9
M.GMCYKK/J7K3KK<N^<]V=N'8?7VSMFY[LG="Q+N7L#+[8V[C\+D=YY\0R3#^
M,;DJZ)ZNHO)*_EE.J21KN:EF/XCUOUP.JO=E?[--5_S"?YB\'0VXNG<?@Z0?
M$!<K1]V[>[/W&B92?I'+2-)LX[2W?MO%8[%O`L/W,8CEDDJO(SL/2/=ZM4T/
MIQZT?+'1@?Y4<^3JOY=WQ3GS517569DZW8Y:IR$F2EJ)\DNY,\M=*K9F27*B
MDDJE8TZU#-,E/H5B2"?=23I7N/6\'R'1??YDF9[(^0^]]H_`SI7#=TUZ9';7
M^GCY)[ZZ#W7M#8F]^L=J[?K*\?&_`T6[M\[DVG@4K>Q>_-NTM?D\=!6_Q"HV
MGMK)1O$::LNVPS```U/6N'`#HYWP;^06Y?D9\>=L;G[*VXVQ^]MDY#*]2?)#
MKZ0TSR;%[\Z[:'$=B8:.:@,N*J<3DZPQ9?%ST<U125&(R=++%-(KACHEC0U/
M7A3TZKE_G%XO=F5["^*R[7Z9VWWW%B>M/F;G-T;#W/D=VTXQ&TJ;9O5-!G^T
M-F8+9]/+E-]]G=78S)RY7"[?IYL?ELQXJBGQ5;2Y%J>3WO4P`H>M_D.K8/BV
M,.OQKZ"CP';F0[]PL'3W75+C>[LL^O+=L4E)M3%4T6_\KJ>6>/);I$7WE1',
M\E3'+*R3.\H=CIB<48]>P?(=57_,GN7M[8_S@K/D#UWG=X97IC^7-\>=L[G^
M474>V,9ELO'V;L/Y/;SS3=D5U%A<>3-G]_\`Q\ZIZ?I=[86FIT>:J1JBB!#5
MB*^\UXG`SGKU?LZ4GP#WMWB?F%WOE>^,ENGS?-[H[KKYD]4[`RZ2QX7HC8NS
M=RY?IO']-X]5`IDW'!UQ7[,SN?!2GF?/Y>OU1'QEVWJ;-?3K75C/RO[]I_C/
MT/OOMQ,#6[SW+B:.CP?6W76)C>;.]H]M[QR%+M3JOK3"01?O&OWKOK,4-$TH
M&BC@DDJ92D$,KK45XZCUZ@].JT/Y>>X._OCCW1E?C)\H,)V]157R9VYD_DIU
M[OCMS>&Q-\ME?DJ0N6^9?4NRZ_K[<^[*';_6N*S.2H]Q;&Q56:%H<#)710QL
ME(=-M3Y!X_ZJ]>X^0ZLD^8]7WA0_%GOVK^-5/+5]]4_56\9>K::DBI9\K)NE
M,3-]LVWJ:O#8ZJW5%`9'Q,-4&I9<DL"S`Q%Q[H"V1J->O8'D*]$H^,U!_*R-
M?T#E^H<_LK)=VUF1K)=F9#<^[=R5'RNRV]JC`90[U'=E%DLDG:%1NMH%K6SU
M+NBG6C@J@0T4>F!5<UDXKUNOR'[.K:9KB&8@,2(I+!"`Y.@V"$@@,?Q_C[;!
M8'XCU['IU05_)'HMF'K#KG+T^Y_AWF]]UW2U:V=I.LTS;?*N"5^P:Z3(2]XU
MF<WIF:NMDBG*1Y!I<;1N,GI"%81&GNVMB,G_`#]:_P!J/V#JT7YZ8/=&Y?A/
M\K\%LG'9S+[MR?Q][7IMO8K;*U;[CR.5.S,N]+1X"+'LF1J,U42)II8J<_<2
MSE4B!=E!TI85HQK3K>!Y#HGE!WCUOW]\J?Y;471?8=!VG2;-Z\[TWYV<NP\U
M/FZ38VV,WTIB-I;<J^UX,?,\>T\GDMXY*.AI,=FT@R/WZS*L`>GG\=PQJ!7'
M6O7'5KNX]N8'=^`S&UMT8BAS^W-P8^IQ&<PF4ITJ\=E<971-3UE!74LH:.HI
M*F%RDB,"K*2#Q[HI8$=QZW0>G5:?\K/J'K/K_K'N//;.V%A=JYVO^4_RNVC5
MY.DH:F+*56T]G?(7?^+VC@7K*^2:L?`;>Q<,<./IP_VU/"`L*JIY\78KQ\^O
M8/D/V=+;^8Q4UU+MSX?FAJLI2F;^8E\,J:J.+GKX&GH9^TZ9*JEKCCV5I<7/
M&=,Z2WIV3B06]^%:#N/$=>X>75AYO<6^E^?]8`_U_J?>P2'.32O6J?+J@3H:
M#X69K8'8F4_F09;95/\`-BF[+W7#W_1=Y[GRN#["VWFZ3?V6?K/'?'BDGR5!
ME*3IQ=G'$2;/J-A:J.OHY%EEEER3UWNP<^9ZW7Y#]@ZOW@T>&'QF0Q^*/QF4
MRF4IH&@R&>\YD*_JU^N_UY]T)8FE3U['IUK\?+CM;Y.=N_(K=W>7QAZO[NW]
ML?\`EJY^''[+3KW>.PMK[![W[Q611\Q>O.PML[NW+@MT;YVSL[H+(2;;V^^-
MQF16'?M1.]*[5-'I6U6&`20.M8].KTNLNQMI=O\`7FR>U-@949S9'8NU,!O;
M:676)Z?[_;^YL93Y;%S24LX2IHZK[6J4303*DT$H:.15=2!5BQ/Q8^76Q3TZ
MK\Z:[*V;@/YF?SHZ\W/O_!X;=.\=A?#&JZ\V+N'=-/C\KN>+'[+[DDS]3L+;
M64KHI<RM'X`U>V,AD,9C#5%K*??JFC#4:XZ]^0Z/]VM48ZCZN[)J\OF]V;:Q
M--L'>%1E-R;"IZ^LWSM['0[>R,E=G=F4F*QV7RE5NO$4RM48Z.FI*JH>KCC6
M.&5RJ-Y6(K4XZ]@>75/G\L++=8;,[;RO2'60Z:[FQL?QCZXWLGRWZ"J=TXU-
M[X'$9]-N;:P'RIV-E<UN+"[<^4&[FRM9G9ZY*U\GF4BR$E528Y88:=K%F8:=
M6.-1CKU?D*?9U>#8?X_[<^VJ'^-OV]>_(?LZ_]'?BJO^+A1?\6__`(#UO^=_
MXN?UIO\`@%_TR?\`*Q_R![8\O]7^JG6_7IR?]#_\%;_>C[UU[IIIO^!U?_P!
M_11?\!_^!G^8;_BY_P"U_P#'#_FU?WOR'^K]O^KAU[SZDXO_`(`4W_`#_-_\
MNO\`XM_ZF_X"_P#-O_B;^_'CUX=-J_\`%XR'_%K_`%4'_`+_`(N7_`2?_B^_
M[3_RJ_[1J][/`?ZO]7R^77NI.-_X%YG_`(M/_%Q7_BV_\"?^`%'_`,7K_JZ?
MT_Z9_'[\>'[/]1^?7AUEG_XN=#_P`_15_P#`C_BX_HA_XMO_`#9_X[_X6]^7
M_5Z]>ZB[9_XLE#_Q8?I4?\>S_P`6/_@7/_P!_P`/^.G_`#>U>]'_`%>G7NO)
M_P`#LU_Q9_I3?YK_`(%_\`3_`,7[_:?^./\`TSW]V\Q_J_;_`*N'6NLH_P"!
M]%_Q;_\`@/4_J_XN7ZJ;_@'_`-,'_'3_``T>]>OV_GUOKAF_^75_Q:O^+O2_
M\77Z_HF_XM/_`%>_^5?_`)"]Z'^K_5Z^G7CUPK_\]A?^+5_P-;_@9_P._P"`
M%5_Q8_\`JX?\=/\`IG\GOP^$]>].GJ3Z#Z_5?T_\&'^^'NOIUKH(,/\`\S=W
MG_S)[_BP8W_BQ?\`,X?I2_\`'Y?]6'_E7_PT>W/7A_E_/_+U[SZ&%_T-]?H?
MI_OOI[KYGK?0$]>_\?UN3_F0_P#F:O\`YEW_`,?W_P`#:?\`X^3_`)L?\=O^
M;VGW8\#P_+K0Z'27]'Y_4GZ?U?K7]/\`C[J./6^@MZ[_`.+UV1_S*O\`X_.?
M_F7'_%Z_S1_YF7_V>'_'3_:?=FX'AQZUZ="E)^D?7]2_I^OU_'^/NG6^F_&_
MHE_X`?\``NK_`.+=_F/\Z_\`G?\`IM_X[_[7?WL^7#KPX=9<A^BE_P"`'_`Z
ME_X'_I_SG_*)_P!7#_CC_M7O8X'_`%?ZCZ=>ZFI^A/\`@J_3Z?0?3W7KW0,[
MY_YF/UG_`,R8_P"!%?\`\?U_S,K^Q_S++_IH_P".W^P]W'X>'Y\?]7IUKH:!
M]!]?]C]?^1^Z>?GUOIEP_P#P#_Y=/_`_)?\`%E_X"?\``^I_5_U</^5K_IHU
M^[>:?ZO]7SZUY]8]O_\`%K@_XM7^;;_BP_\`%D_SL_\`Q;O^;?\`J_\`F[J]
MZ/'K8Z06X?\`F9.T?^94_P#`6;_B^?\`,S_\U4?\>A_TR_\`'7_FWK]['#_5
M7_5Z=:Z%L_\`%?I]?]A_C[T/B'6^@JZQ_P`QNS_F5O\`Q_6=_P"96_\``;_.
:I_Q^'_9\?\KW^UV]V;AY?EUX="K[IU[K_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
